|
|||||
|
|
Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin,halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial |
|
| Authors: | Robert J Morgan Timothy W Synold Jeffrey A Longmate David I Quinn David Gandara Heinz-Josef Lenz Christopher Ruel Bixin Xi Michael D Lewis A Dimitrios Colevas James Doroshow Edward M Newman |
| Institution: | 1. Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 E. Duarte Rd., Duarte, CA, 91010, USA 2. Department of Cancer Biology, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA 3. Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, 91010, USA 4. Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, 90033, USA 5. Division of Medical Oncology, University of California, Davis Cancer Center, Sacramento, CA, USA 6. Eisai Research Institute, Andover, MA, 01810, USA 8. Edward P. Evans Foundation, Casanova, VA, 20139, USA 7. Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, 20892, USA 9. Stanford Cancer Center, Stanford, CA, 94305, USA 10. Division of Cancer Treatment and Diagnosis6, National Cancer Institute, Bethesda, MD, 20892, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |